THIS DOCUMENT IS IN DRAFT FORM, INCOMPLETE AND SUBJECT TO CHANGE AND THAT THE INFORMATION MUST BE READ IN CONJUNCTION WITH THE SECTION HEADED “WARNING” ON THE COVER OF THIS DOCUMENT. DIRECTORS AND SENIOR MANAGEMENT BOARD OF DIRECTORS Our Board of Directors will comprise 9 Directors upon [REDACTED], including 3 executive Directors, 3 non-executive Directors and 3 independent non-executive Directors. Our Directors are elected to serve a term of three years, which is renewable upon reelection and/or reappointment. The following table sets out information in respect of the Directors of our Company. Date of Date of appointment joining our as a Roles and Name Age Position Group Director responsibilities Dr. QIAN Jianzhong 73 Executive Director January 13, August 25, Overall management of 2003 2020 the business, strategy and corporate development of the Group Dr. FAN Li 50 Executive Director January 13, October 28, Management of 2003 2020 operating and legal affairs of the Company Dr. ZENG Xiaolan 47 Executive Director May 16, 2004 March 29, Management of business 2021 and market development strategy and regulatory affairs of the Company Dr. HUA Ping 57 Non-executive October 28, October 28, Participating in Director 2020 2020 decision-making of important matters of our Group Ms. HAN Li (韓黎) 39 Non-executive November 4, November 4, Participating in Director 2020 2020 decision-making of important matters of our Group Ms. XU Juan (許娟) 43 Non-executive March 29, 2021 March 29, Participating in Director 2021 decision-making of important matters of our Group Mr. George S. GEH 60 Independent [*] [*] Providing independent non-executive advice and judgment to Director our Board Mr. LEUNG Ieng Kit 54 Independent [*] [*] Providing independent (梁英杰) non-executive advice and judgment to Director our Board Mr. LU Chao (陸超) 37 Independent [*] [*] Providing independent non-executive advice and judgment to Director our Board Executive Directors Dr. QIAN Jianzhong, aged 73, is the founder of our Group. He was appointed as a Director on August 25, 2020 and re-designated to an executive Director on July 1, 2021. Dr. Qian Jianzhong is – 191 – THIS DOCUMENT IS IN DRAFT FORM, INCOMPLETE AND SUBJECT TO CHANGE AND THAT THE INFORMATION MUST BE READ IN CONJUNCTION WITH THE SECTION HEADED “WARNING” ON THE COVER OF THIS DOCUMENT. DIRECTORS AND SENIOR MANAGEMENT mainly responsible for the overall management of the business, strategy and corporate development of the Group. Dr. Qian Jianzhong has been serving as the chairman, director and president of our Group for nearly 20 years since January 2003 when he founded our Group. Prior to the establishment of our Group, Dr. Qian Jianzhong worked as a project manager in the CIT business unit of Siemens Corporation from July 1993 to January 2003, whose shares are listed on Frankfurt Stock Exchange (ticker symbol: SIE) and New York Stock Exchange (ticker symbol: SIEGY). From July 1990 to June 1993, Dr. Qian Jianzhong served as the principal research scientist at Siemens Gammasonics Inc. Dr. Qian Jianzhong obtained his master’s degree and doctorate degree in electrical/computer engineering from Virginia Polytechnic Institute and State University in the U.S. in 1985 and 1990, respectively. Dr. Qian Jianzhong was awarded as “Siemens Inventor of the Year” by Siemens Corporate in June 1999 and received fellowship position in American Institute for Medical and Biological Engineering in March 2006. Dr. FAN Li, aged 50, is one of the co-founders of our Group. She was appointed as a Director on October 28, 2020 and re-designated to an executive Director on July 1, 2021. Dr. Fan Li is mainly responsible for management of operating and legal affairs of the Company. Dr. Fan Li joined our Group in January 2003 and has been serving as a director and chief operating officer of our Group since January 2003 onwards. She has also consecutively served as vice president of our Group from January 2003 to March 2021. Prior to the establishment of our Group, from March 2000 to January 2003, Dr. Fan Li worked at Siemens Corporate Research Inc. as a technical staff. Dr. Fan Li graduated from Beijing Institute of Posts and Telecommunications (currently known as Beijing University of Posts and Telecommunications （北京郵電大學）) in the PRC with a bachelor’s degree in computer engineering in July 1992. She received her master’s degree in electrical engineering from Beijing University of Technology (北京工業大學) in the PRC in March 1995 and doctorate degree in electrical engineering from University of Missouri-Columbia in the U.S. in December 2000. Dr. ZENG Xiaolan, aged 47, is one of the co-founders of our Group. She was appointed as a Director on March 29, 2021 and re-designated to an executive Director on July 1, 2021. Dr. Zeng Xiaolan is mainly responsible for management of business and market development strategy and regulatory affairs of the Company. Dr. Zeng Xiaolan has been working in our Group for more than 15 years since she joined our Group in May 2004. In our Group, Dr. Zeng Xiaolan consecutively served as the vice president of clinical affairs from May 2004 to May 2005, the executive vice president of business and market development from May 2005 to March 2021 and the chief strategy officer since March 2021. Prior to the establishment of our Group, she worked at R2 Technology Inc., a medical technology company, as an algorithm architect from August 2000 to May 2004. Dr. Zeng Xiaolan graduated from University of Science and Technology of China (中國科學技術 大學) in the PRC with a bachelor’s degree in electrical engineering in July 1995. Dr. Zeng Xiaolan received her master’s degree, master degree of philosophy and doctorate degree in engineering and applied science from Yale University in the U.S. in December 1995, May 1997 and May 2000, respectively. – 192 – THIS DOCUMENT IS IN DRAFT FORM, INCOMPLETE AND SUBJECT TO CHANGE AND THAT THE INFORMATION MUST BE READ IN CONJUNCTION WITH THE SECTION HEADED “WARNING” ON THE COVER OF THIS DOCUMENT. DIRECTORS AND SENIOR MANAGEMENT Non-executive Directors Dr. HUA Ping, aged 57, was appointed as a non-executive Director on October 28, 2020 and re- designated as a non-executive Director with effect from July 1, 2021. He is primarily responsible for participating in decision-making of important matters of our Group. Dr. Hua has been a non-executive Director of our company since October 28, 2020. Dr. Hua is currently a Managing Partner of SBCVC (軟銀中國資本). Starting from 2000, he has led the investment into many technology companies in TMT and healthcare. Prior to joining SBCVC, he was an associate with McKinsey & Consulting Company Inc., Shanghai from September 6, 1998 to January 14, 2000 and worked as a Principal Research Scientist at Siemens Medical Systems USA, Inc. as a principal engineer and principal research scientist from April 16, 1990 to August 21, 1998. Dr. Hua graduated from Shanghai Jiaotong University (上海交通大學) with a bachelor’s degree in electrical engineering in July 1982. He then obtained his Ph.D. from the University of Wisconsin- Madison in 1984 and MBA degree from the Kellogg School of Management, Northwestern University in 1998. Ms. HAN Li (韓黎), aged 39, was appointed as a non-executive Director on November 4, 2020 and re-designated as a non-executive Director with effect from July 1, 2021. She is primarily responsible for participating in decision-making of important matters of our Group. Ms. Han has been working in Bank of China Group Investment Limited (中銀集團投資有限公 司), which is a subsidiary of Bank of China Limited (中國銀行股份有限公司), a Stock Exchange listed company (stock code: 3988) since 2008. Since 2019, she has been serving as the head of healthcare investment division of the group. Ms. Han received her bachelor’s degree in economics from Universite de Franch-Comte in 2004. She obtained her master’s degree in finance and in electronic commerce, from Universite de Bourgogne and Universite de Franch-Comte, respectively. Ms. XU Juan (許娟), aged 43, was appointed as a non-executive Director on March 29, 2021 and re-designated as a non-executive Director with effect from July 1, 2021. She is primarily responsible for participating in decision-making of important matters of our Group. Ms. Xu has been serving as a director at QuantumPharm Inc. since September 28, 2020 and a director at Guangzhou Xaircraft Technology Co. Ltd. (廣州極飛科技有限公司), which is a company focusing on developing drones, responsible for reviewing reports submitted by the management and voting for major issues. Ms. Xu also serves as investment partner at SBIA (Hong Kong) Limited since January 2020, responsible for the company’s investment business in China. Prior to that, she served as the director and general manager at Goldman Sachs Asia L.L.C., responsible for its investment business in China from August 2009 to January 2020. Ms. Xu obtained her master’s degree in international business from Waseda University in March 2003 and MBA degree from Harvard Business School in June 2008. – 193 – THIS DOCUMENT IS IN DRAFT FORM, INCOMPLETE AND SUBJECT TO CHANGE AND THAT THE INFORMATION MUST BE READ IN CONJUNCTION WITH THE SECTION HEADED “WARNING” ON THE COVER OF THIS DOCUMENT. DIRECTORS AND SENIOR MANAGEMENT Independent Non-executive Directors Mr. George S. GEH, aged 60, was appointed as our independent non-executive Director on July 1, 2021. He is responsible for providing independent advice and judgment to our Board. From January 2019 to December 2020, Mr. Geh served as a managing director at Lone Star Funds. From January 2016 to December 2018, Mr. Geh served as the managing director at a turnaround and restructuring consulting firm, AlixPartners, leading its China business.